STOCK TITAN
  1. Home
  2. Sec-filings
  3. AKRO
  4. [Form 4] Akero Therapeutics, Inc. Insider Trading Activity

[Form 4] Akero Therapeutics, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock AKRO logo
Akero Therapeutics

NASDAQ:AKRO

AKRO Rankings

#1603 Ranked by Market Cap
N/A Ranked by Dividends

AKRO Latest News

Oct 7, 2025
Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025
Aug 28, 2025
Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
Aug 14, 2025
Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
Aug 8, 2025
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Jun 3, 2025
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

AKRO Latest SEC Filings

Oct 7, 2025
[SCHEDULE 13G] Akero Therapeutics, Inc. SEC Filing
Oct 7, 2025
[144] Akero Therapeutics, Inc. SEC Filing
Oct 3, 2025
[Form 4] Akero Therapeutics, Inc. Insider Trading Activity
Sep 29, 2025
[8-K] Akero Therapeutics, Inc. Reports Material Event
Sep 10, 2025
[Form 4] Akero Therapeutics, Inc. Insider Trading Activity

AKRO Stock Data

3.68B
71.54M
1.14%
116.23%
11.11%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO